Benzinga · Feb 19, 2026
Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45
Guggenheim analyst Debjit Chattopadhyay maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $41 to $45.
NA
NASDAQ · NAMS
NewAmsterdam Pharma Company N.V.
Healthcare · Biotechnology
$26.79
Down-$0.61 (-2.23%)
Updated Aug 28, 2026, 7:45 AM
SID Score
4.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.1B
- P/E ratio
- -19.49
- Dividend yield
- 0.00%
- 52-week range
- $25.74 – $42.21
- Volume
- 626.83K
- Avg. volume
- 1.15M
Price performance
NAMS price history
1M range · 21 trading sessions · Daily adjusted prices
NAMS closed at $26.79 after 21 trading sessions, down 5.87% for the selected period.
- Last close
- $26.79
- Period change
- -5.87%
- Period low
- $26.67
- Period high
- $28.53
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $27.15 | $27.60 | $26.67 | $26.79 | 626.83K |
| Aug 26, 2026 | $27.22 | $27.61 | $26.71 | $27.40 | 758.73K |
| Aug 25, 2026 | $27.00 | $28.01 | $27.00 | $27.34 | 1.99M |
| Aug 24, 2026 | $27.80 | $27.97 | $26.6701 | $26.85 | 1.15M |
| Aug 21, 2026 | $27.99 | $28.35 | $27.66 | $27.87 | 525.43K |
| Aug 20, 2026 | $28.26 | $28.43 | $27.53 | $27.78 | 744.36K |
| Aug 19, 2026 | $28.00 | $28.76 | $27.64 | $28.53 | 1.03M |
| Aug 18, 2026 | $26.66 | $27.82 | $26.43 | $27.25 | 948.92K |
| Aug 17, 2026 | $26.93 | $27.3894 | $26.51 | $26.90 | 834.97K |
| Aug 14, 2026 | $26.26 | $27.06 | $26.01 | $26.98 | 959.92K |
| Aug 13, 2026 | $27.85 | $28.03 | $26.63 | $26.67 | 1.23M |
| Aug 12, 2026 | $27.945 | $28.18 | $27.45 | $27.83 | 1.63M |
| Aug 11, 2026 | $27.95 | $28.63 | $27.29 | $27.62 | 2.34M |
| Aug 10, 2026 | $28.08 | $28.97 | $27.43 | $27.98 | 901.79K |
| Aug 7, 2026 | $28.05 | $28.23 | $27.51 | $27.96 | 572.01K |
| Aug 6, 2026 | $27.63 | $27.98 | $27.30 | $27.67 | 1.65M |
| Aug 5, 2026 | $27.33 | $27.845 | $25.74 | $27.42 | 1.65M |
| Aug 4, 2026 | $27.82 | $28.06 | $27.00 | $27.55 | 1.08M |
| Aug 3, 2026 | $27.67 | $27.89 | $26.91 | $27.49 | 1.01M |
| Jul 31, 2026 | $28.37 | $28.76 | $27.31 | $27.79 | 956.63K |
| Jul 30, 2026 | $27.93 | $28.72 | $26.99 | $28.46 | 611.37K |
Latest NAMS news
The latest Smart Investors Daily articles mentioning NAMS.
Stock researchCompany · Overview
NAMS research
Overview
Company profile and research snapshot.
Company profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $44.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Jun 30, 2026 | RBC Capital | Outperform | — |
| Feb 19, 2026 | Guggenheim | Buy | — |
| Feb 18, 2026 | Needham | Buy | — |
| Jan 21, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 18, 2026
Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co
Benzinga · Feb 18, 2026
Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $48
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $46 to $48.
Yahoo · Feb 18, 2026
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY-- -- Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metabolic syndrome expected by year-end 2026 -- -- $728.9 million in cash, cash equivalents and marketable securities at December 31, 2025 -- NAARDEN, the Netherlands and MIAM
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
